OVID
What one share of Ovid Therapeutics holds
Pharmaceutical Preparations
Ovid is a biopharmaceutical company that is dedicated to developing small molecule medicines for brain disorders with significant unmet need. These potential medicines targeting the central nervous system (“CNS”) are designed to potentially halt the course of brain disease by quelling neuronal hyperexcitation and alleviating the most impactful patient symptoms.
Ovid Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.01 |
|---|---|
| Profit | −$0.28 |
| Cash and investments | $0.06 |
| Book value | $1.14 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | — | −$2.28 | $0.00 | −$1.81 | — | $5.01 |
| 2017 | — | −$3.35 | $0.00 | −$1.63 | — | $3.39 |
| 2018 | — | −$2.11 | $0.00 | −$1.85 | — | $1.57 |
| 2020 | — | −$1.39 | $0.00 | −$0.88 | — | $0.66 |
| 2021 | — | $1.76 | $0.00 | $1.74 | — | $2.55 |
| 2022 | $0.02 | −$0.77 | $0.02 | −$0.80 | — | $1.88 |
| 2023 | $0.01 | −$0.74 | $0.00 | −$0.65 | — | $1.24 |
| 2024 | $0.01 | −$0.37 | $0.00 | −$0.78 | — | $0.96 |
| 2025 | $0.10 | −$0.23 | $0.00 | −$0.51 | — | $1.00 |